Comparative measurement of spinal CSF microdialysate concentrations and concomitant antinociception of morphine and morphine-6β-glucuronide in rats

Life Sciences

Volumn 80, Issue 14, 2007, Pages 1319-1326

  Okura, Takashi ^a,b   Komiyama, Noriyuki ^a   Morita, Yuki ^a   Kimura, Midori ^a   Deguchi, Yoshiharu ^b   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Microdialysis; Morphine; Morphine 6 glucuronide

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE; OPIATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG POTENCY; MALE; MICRODIALYSIS; NONHUMAN; RAT;

ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; CEREBROSPINAL FLUID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; MORPHINE; MORPHINE DERIVATIVES; PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

RATTUS;

EID: 33847331581     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.12.018     Document Type: Article

References (29)

1. Aasmundstad T.A., Mørland J., and Paulsen R.E. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. The Journal of Pharmacology and Experimental Therapeutics 275 (1995) 435-441
2. Abbott F.V., and Palmour R.M. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sciences 43 (1988) 1685-1695
3. Abbott F.V., Ocvirk R., Najafee R., and Franklin K.B. Improving the efficiency of the formalin test. Pain 83 (1999) 561-569
4. Bickel U., Schumacher O.P., Kang Y.S., and Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. The Journal of Pharmacology and Experimental Therapeutics 278 (1996) 107-113
5. Bouw M.R., and Hammarlund-Udenaes M. Methodological aspects of the use of a calibrator in in vivo microdialysis - further development of the retrodialysis method. Pharmaceutical Research 15 (1998) 1673-1679
6. Bouw M.R., Xie R., Tunblad K., and Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. British Journal of Pharmacology 134 (2001) 1796-1804
7. 3H-morphine-6β-glucuronide binding in brain membranes and an MOR-1-transfected cell line. The Journal of Pharmacology and Experimental Therapeutics 282 (1997) 1291-1297
8. Carrupt P.A., Testa B., Bechalany A., Tayar N.E., Descas P., and Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. Journal of Medicinal Chemistry 34 (1991) 1272-1275
9. Chou R.C., and Levy G. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. The Journal of Pharmacology and Experimental Therapeutics 219 (1981) 42-48
10. Deguchi Y., Inabe K., Tomiyasu K., Nozawa K., Yamada S., and Kimura R. Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharmaceutical Research 12 (1995) 1838-1844
11. Deguchi Y., Nozawa K., Yamada S., Yokoyama Y., and Kimura R. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. The Journal of Pharmacology and Experimental Therapeutics 280 (1997) 551-560
12. Frances B., Gout R., Monsarrat B., Cros J., and Zajak J.M. Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. The Journal of Pharmacology and Experimental Therapeutics 262 (1992) 25-31
13. Gong Q.L., Hender T., Hender J., Björkman R., and Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. European Journal of Pharmacology 193 (1991) 47-56
14. Kilpatrick G.J., and Smith T.W. Morphine-6-glucuronide: actions and mechanism. Medicinal Research Reviews 25 (2005) 521-544
15. Marsala M., Malmberg A.B., and Yaksh T.L. The spinal loop dialysis catheter: characterization of use in the unanesthetized rat. Journal of Neuroscience Methods 62 (1995) 43-53
16. Meng Q.C., Cepeda M.S., Kramer T., Zou H., Matoka D.J., and Farrar J. High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites by two-step solid-phase extraction. Journal of Chromatography B. Biomedical Sciences and Applications 742 (2000) 115-123
17. Murray C.W., Porreca F., and Cowan A. Methodological refinements to the mouse paw formalin test. An animal model of tonic pain. Journal of Pharmacological Methods 20 (1988) 175-186
18. Okura T., Saito M., Nakanishi M., Komiyama N., Fujii A., Yamada S., and Kimura R. Different distribution of morphine and morphine-6β-glucuronide after intracerebroventricular injection in rats. British Journal of Pharmacology 140 (2003) 211-217
19. Osborne R., Joel S., Trew D., and Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the metabolite morphine-6-glucuronide. Clinical Pharmacology and Therapeutics 47 (1990) 12-19
20. Osborne P.B., Chieng B., and Christie M.J. Morphine-6β-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus. British Journal of Pharmacology 131 (2000) 1422-1428
21. Pan Y.X., Xu J., Bolan E., Abbadie C., Chang A., Zuckerman A., Rossi G., and Pasternak G.W. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Molecular Pharmacology 56 (1999) 396-403
22. Pasternak G.W., and Standifer K.M. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends in Pharmacological Sciences 16 (1995) 344-350
23. Paul D., Standifer K.M., Inturrisi C.E., and Pasternak G.W. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. The Journal of Pharmacology and Experimental Therapeutics 251 (1989) 77-83
24. Reisine T., and Pasternak G. Opioid analgesics and antagonists. In: Hardman J.G., Gilman A.G., and Limbird L.E. (Eds). Goodman and Gillman's the Pharmaceutical Basis of Therapeutics. 9th edn. (1996), McGraw-Hill, New York 521-555
25. Selley D.E., Cao C.C., Sexton T., Schwegel J.A., Martin T.J., and Childers S.R. μ Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochemical Pharmacology 62 (2001) 447-455
26. Stain-Texier F., Boschi G., Sandouk P., and Scherrmann J.M. Elevated concentrations of morphine 6-beta-d-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. British Journal of Pharmacology 128 (1999) 917-924
27. Vaz Z.R., Filho V.C., Yunes R.A., and Calixto J.B. Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice. The Journal of Pharmacology and Experimental Therapeutics 278 (1996) 304-312
28. Wu D., Kang Y.S., Bickel U., and Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metabolism and Disposition 25 (1997) 768-771
29. Yoshimura H., Oguri K., and Tsukamoto H. Metabolism of drugs. The synthesis of codeine and morphine glucuronides. Chemical and Pharmaceutical Bulletin 16 (1968) 2114-2119